{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T09:34:25Z","timestamp":1773221665130,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100022718","name":"Department of Transport and Planning","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100022718","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Medical cannabis is now commonly prescribed for a range of chronic health conditions. Many medical cannabis products contain delta-9-tetrahydrocannabinol (THC), the intoxicating component in cannabis, though it is unclear whether these products produce impairment when used as prescribed and at therapeutic doses. With current Australian laws prohibiting driving with any amount of THC in one\u2019s system, this trial aims to generate novel data on the impact of prescribed medical cannabis on real-world driving performance to inform road safety policy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This is a two-phase trial, with the first phase being a semi-naturalistic cohort study involving 72 patients with physician-diagnosed chronic pain, anxiety, or insomnia (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200924 per group) who will complete repeated on-track driving assessments before and after consuming a standard dose of their medical cannabis prescription. The second phase is a randomised, placebo-controlled, double-blind, and crossover study involving 24 healthy participants who will complete the same repeated on-track driving assessments before and after consuming either alcohol (0.05% blood alcohol concentration) or placebo. Participants in both phases will also complete repeated cognitive assessments and assessments of subjective state and provide biological samples for analysis of cannabinoid (phase 1) and alcohol (phase 2) concentrations. The primary outcome measure is lateral vehicular control. Data will be analysed using a series of mixed-effect and generalised linear mixed models to assess changes in outcome measures over time.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration numbers<\/jats:title>\n                    <jats:p>ACTRN 17\/09\/2024 for 12624001118594 and 24\/09\/2024 for 12624001163594.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-026-09512-x","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T08:26:51Z","timestamp":1770366411000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of prescribed medical cannabis and alcohol on real-world driving performance (CAN-TRACK): a study protocol for a two-phase trial"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8559-6995","authenticated-orcid":false,"given":"Thomas R.","family":"Arkell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amie C.","family":"Hayley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blair","family":"Aitken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brooke","family":"Manning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke A.","family":"Downey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"9512_CR1","unstructured":"Therapeutic Goods Adminsitration. Medicinal Cannabis Special Access Scheme Category B data: Australian Government; 2023 [Available from: https:\/\/www.tga.gov.au\/medicinal-cannabis-special-access-scheme-category-b-data."},{"issue":"2","key":"9512_CR2","doi-asserted-by":"publisher","first-page":"e2254752","DOI":"10.1001\/jamanetworkopen.2022.54752","volume":"6","author":"CA Zamarripa","year":"2023","unstructured":"Zamarripa CA, Spindle TR, Surujunarain R, Weerts EM, Bansal S, Unadkat JD, et al. Assessment of orally administered \u03949-tetrahydrocannabinol when coadministered with cannabidiol on \u03949-tetrahydrocannabinol pharmacokinetics and pharmacodynamics in healthy adults: a randomized clinical trial. JAMA Netw Open. 2023;6(2):e2254752-e.","journal-title":"JAMA Netw Open"},{"issue":"7","key":"9512_CR3","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1177\/02698811211021583","volume":"35","author":"TR Spindle","year":"2021","unstructured":"Spindle TR, Martin EL, Grabenauer M, Woodward T, Milburn MA, Vandrey R. Assessment of cognitive and psychomotor impairment, subjective effects, and blood THC concentrations following acute administration of oral and vaporized cannabis. J Psychopharmacol. 2021;35(7):786\u2013803.","journal-title":"J Psychopharmacol"},{"issue":"9","key":"9512_CR4","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1007\/s00213-019-05246-8","volume":"236","author":"TR Arkell","year":"2019","unstructured":"Arkell TR, Lintzeris N, Kevin RC, Ramaekers JG, Vandrey R, Irwin C, et al. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Psychopharmacology. 2019;236(9):2713\u201324.","journal-title":"Psychopharmacology"},{"issue":"11","key":"9512_CR5","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1007\/s00213-022-06248-9","volume":"239","author":"N Hutten","year":"2022","unstructured":"Hutten N, Arkell TR, Vinckenbosch F, Schepers J, Kevin RC, Theunissen EL, et al. Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis. Psychopharmacology. 2022;239(11):3731\u201341.","journal-title":"Psychopharmacology"},{"key":"9512_CR6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.neubiorev.2021.01.003","volume":"126","author":"D McCartney","year":"2021","unstructured":"McCartney D, Arkell TR, Irwin C, McGregor IS. Determining the magnitude and duration of acute \u03949-tetrahydrocannabinol (\u03949-THC)-induced driving and cognitive impairment: a systematic and meta-analytic review. Neurosci Biobehav Rev. 2021;126:175\u201393.","journal-title":"Neurosci Biobehav Rev"},{"key":"9512_CR7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.copsyc.2019.04.002","volume":"30","author":"TR Spindle","year":"2019","unstructured":"Spindle TR, Bonn-Miller MO, Vandrey R. Changing landscape of cannabis: novel products, formulations, and methods of administration. Curr Opin Psychol. 2019;30:98\u2013102.","journal-title":"Curr Opin Psychol"},{"issue":"2","key":"9512_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/jat\/bkx012","volume":"41","author":"R Vandrey","year":"2017","unstructured":"Vandrey R, Herrmann ES, Mitchell JM, Bigelow GE, Flegel R, LoDico C, et al. Pharmacokinetic profile of oral cannabis in humans: blood and oral fluid disposition and relation to pharmacodynamic outcomes. J Anal Toxicol. 2017;41(2):83\u201399.","journal-title":"J Anal Toxicol"},{"key":"9512_CR9","doi-asserted-by":"publisher","unstructured":"O\u2019Brien K, Blair P. Routes of Administration, Pharmacokinetics and Safety of Medicinal Cannabis. In: Medicinal Cannabis and CBD in Mental Healthcare. Springer, Cham: Springer; 2021. https:\/\/doi.org\/10.1007\/978-3-030-78559-8_11.","DOI":"10.1007\/978-3-030-78559-8_11"},{"issue":"3","key":"9512_CR10","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1373\/clinchem.2012.194381","volume":"59","author":"RL Hartman","year":"2013","unstructured":"Hartman RL, Huestis MA. Cannabis effects on driving skills. Clin Chem. 2013;59(3):478\u201392.","journal-title":"Clin Chem"},{"key":"9512_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.aap.2020.105784","volume":"148","author":"TR Arkell","year":"2020","unstructured":"Arkell TR, Lintzeris N, Mills L, Suraev A, Arnold JC, McGregor IS. Driving-related behaviours, attitudes and perceptions among Australian medical cannabis users: results from the CAMS 18-19 survey. Accid Anal Prev. 2020;148:105784.","journal-title":"Accid Anal Prev"},{"issue":"8","key":"9512_CR12","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1002\/cbdv.200790152","volume":"4","author":"MA Huestis","year":"2007","unstructured":"Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4(8):1770\u2013804.","journal-title":"Chem Biodivers"},{"key":"9512_CR13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.neubiorev.2021.01.003","volume":"126","author":"D McCartney","year":"2021","unstructured":"McCartney D, Arkell TR, Irwin C, McGregor IS. Determining the magnitude and duration of acute delta(9)-tetrahydrocannabinol (Delta(9)-THC)-induced driving and cognitive impairment: a systematic and meta-analytic review. Neurosci Biobehav Rev. 2021;126:175\u201393.","journal-title":"Neurosci Biobehav Rev"},{"issue":"7","key":"9512_CR14","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1177\/02698811211021583","volume":"35","author":"TR Spindle","year":"2021","unstructured":"Spindle TR, Martin EL, Grabenauer M, Woodward T, Milburn MA, Vandrey R. Assessment of cognitive and psychomotor impairment, subjective effects, and blood THC concentrations following acute administration of oral and vaporized cannabis. J Psychopharmacol. 2021;35(7):786\u2013803.","journal-title":"J Psychopharmacol"},{"key":"9512_CR15","doi-asserted-by":"publisher","unstructured":"Veldstra JL, Bosker WM, de Waard D, Ramaekers JG, Brookhuis KA. Comparing treatment effects of oral THC on simulated and on-the-road driving performance: testing the validity of driving simulator drug research. Psychopharmacology (Berl). 2015;232(16):2911\u20139. https:\/\/doi.org\/10.1007\/s00213-015-3927-9. Epub 2015 May 10. PMID: 25957748; PMCID: PMC4513227.","DOI":"10.1007\/s00213-015-3927-9"},{"key":"9512_CR16","doi-asserted-by":"crossref","unstructured":"Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt Impulsiveness Scale. J Clin Psychol. 1995;51(6):768\u201374.","DOI":"10.1002\/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1"},{"issue":"2","key":"9512_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jpain.2003.12.005","volume":"5","author":"G Tan","year":"2004","unstructured":"Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the brief pain inventory for chronic nonmalignant pain. J Pain. 2004;5(2):133\u20137.","journal-title":"J Pain"},{"issue":"6","key":"9512_CR18","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr.","year":"1992","unstructured":"Ware JE Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473\u201383.","journal-title":"Med Care"},{"key":"9512_CR19","doi-asserted-by":"crossref","unstructured":"Lovibond S. Manual for the depression anxiety stress scales. Psychology Foundation of Australia. 1995.","DOI":"10.1037\/t01004-000"},{"issue":"2","key":"9512_CR20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/j.1559-1816.2003.tb01896.x","volume":"33","author":"CS Dula","year":"2003","unstructured":"Dula CS, Ballard ME. Development and evaluation of a measure of dangerous, aggressive, negative emotional, and risky driving. J Appl Soc Psychol. 2003;33(2):263\u201382.","journal-title":"J Appl Soc Psychol"},{"issue":"10-11","key":"9512_CR21","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1080\/00140139008925335","volume":"33","author":"J Reason","year":"1990","unstructured":"Reason J, Manstead A, Stradling S, Baxter J, Campbell K. Errors and violations on the roads: a real distinction? Ergonomics. 1990;33(10\u201311):1315\u201332.","journal-title":"Ergonomics"},{"key":"9512_CR22","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2147\/IJGM.S19639","volume":"4","author":"JC Verster","year":"2011","unstructured":"Verster JC, Roth T. Standard operation procedures for conducting the on-the-road driving test, and measurement of the standard deviation of lateral position (SDLP). Int J Gen Med. 2011;4:359\u201371.","journal-title":"Int J Gen Med"},{"issue":"21","key":"9512_CR23","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1001\/jama.2020.21218","volume":"324","author":"TR Arkell","year":"2020","unstructured":"Arkell TR, Vinckenbosch F, Kevin RC, Theunissen EL, McGregor IS, Ramaekers JG. Effect of cannabidiol and delta9-tetrahydrocannabinol on driving performance: a randomized clinical trial. JAMA. 2020;324(21):2177\u201386.","journal-title":"JAMA"},{"issue":"7","key":"9512_CR24","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/1099-1077(200010)15:7<551::AID-HUP236>3.0.CO;2-P","volume":"15","author":"JG Ramaekers","year":"2000","unstructured":"Ramaekers JG, Robbe HW, O\u2019Hanlon JF. Marijuana, alcohol and actual driving performance. Hum Psychopharmacol Clin Exp. 2000;15(7):551\u20138.","journal-title":"Hum Psychopharmacol Clin Exp"},{"issue":"1-2","key":"9512_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3109\/00207459008994241","volume":"52","author":"T \u00c5kerstedt","year":"1990","unstructured":"\u00c5kerstedt T, Gillberg M. Subjective and objective sleepiness in the active individual. Int J Neurosci. 1990;52(1\u20132):29\u201337.","journal-title":"Int J Neurosci"},{"key":"9512_CR26","unstructured":"Hart S. Development of NASA-TLX (Task Load Index): results of empirical and theoretical research. Human mental workload\/Elsevier. 1988."},{"issue":"1","key":"9512_CR27","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1530-0277.1993.tb00739.x","volume":"17","author":"CS Martin","year":"1993","unstructured":"Martin CS, Earleywine M, Musty RE, Perrine MW, Swift RM. Development and validation of the Biphasic Alcohol Effects Scale. Alcohol Clin Exp Res. 1993;17(1):140\u20136.","journal-title":"Alcohol Clin Exp Res"},{"issue":"2","key":"9512_CR28","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/jat\/bkaa057","volume":"45","author":"M Di Rago","year":"2021","unstructured":"Di Rago M, Pantatan S, Hargreaves M, Wong K, Mantinieks D, Kotsos A, et al. High throughput detection of 327 drugs in blood by LC-MS-MS with automated data processing. J Anal Toxicol. 2021;45(2):154\u201383.","journal-title":"J Anal Toxicol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09512-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09512-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09512-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:15:37Z","timestamp":1773144937000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09512-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9512"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09512-x","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Swinburne University\u2019s Human Research Ethics Committee has approved this project (Project ID: 8178).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"The study investigators declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"200"}}